CD274 and B-cell non-Hodgkin lymphoma: There are many studies indicating that the inhibition of HDACs increased the expression of PD-L1 protein in human and murine cancer cells and consequently augmented the efficacy of anti-PD-L1 therapy, e.g., in B-cell lymphomas [98] and mouse experimental tumor models [99].